Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2001, p. 2110-2114, Vol. 45, No. 7
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2110-2114.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Discrimination of SHV
-Lactamase Genes by
Restriction Site Insertion-PCR
Aroonwadee
Chanawong,1
Fatima Hannachi
M'Zali,1
John
Heritage,1
Aroonlug
Lulitanond,2 and
Peter
Michael
Hawkey1,*
Division of Microbiology, School of
Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT,
United Kingdom,1 and Department of
Clinical Microbiology, Faculty of Associated Medical Sciences, Khon
Kaen University, Khon Kaen 40002, Thailand2
Received 8 September 2000/Returned for modification 15 January
2001/Accepted 10 April 2001
 |
ABSTRACT |
Restriction site insertion-PCR (RSI-PCR) is a simple, rapid
technique for detection of point mutations. This technique exploits primers with one to three base mismatches near the 3' end to modulate a
restriction site. We have developed this technique to identify described mutations of the blaSHV genes for
differentiation of SHV variants that cannot be distinguished easily by
other techniques. To validate this method, eight standard strains were
used, each producing a different SHV
-lactamase: SHV-1, SHV-2,
SHV-3, SHV-4, SHV-5, SHV-6, SHV-8, and SHV-18. Mismatch primers were
designed to detect mutations affecting amino acids at positions 8 (SspI), 179 (HinfI), 205 (PstI),
238 (Gly
Ala) (BsrI), and 240 (NruI) of
blaSHV genes. All amplimers of the
blaSHV genes used in this study yielded the
predicted restriction endonuclease digestion products. In addition,
this study also makes theoretical identification of
blaSHV-6, blaSHV-8, and
12 novel blaSHV variants using the PCR-restriction fragment length polymorphism (RFLP) technique possible.
By using a combination of PCR-RFLP and RSI-PCR techniques, up to 27 SHV
variants can now be distinguished rapidly and reliably. These simple
techniques are readily applied to epidemiological studies of the SHV
-lactamases and may be extended to the characterisation of other
resistance determinants.
 |
INTRODUCTION |
SHV extended-spectrum
-lactamases
are spread worldwide in members of the family
Enterobacteriaceae (8, 9). Methods used to
characterize these enzymes, including isoelectric focusing and
nucleotide sequence analysis, are time-consuming, expensive, or both.
PCR-single-strand conformational polymorphism (PCR-SSCP) analysis is
useful for characterization of the genes encoding SHV
-lactamases,
particularly for detection of new SHV variants, or where a single
strain harbors different blaSHV genes
(13). Mutations leading to the production of some SHV
variants, however, yield PCR-SSCP patterns that are difficult to
differentiate, and the technique relies upon relatively expensive
instrumentation that is not available routinely to diagnostic
laboratories. Recently, the ligase chain reaction has been developed
and has been successful for typing known SHV variants
(11). That technique, however, needs special reagents or a
detection kit, which may be expensive, making routine application
impractical. Hence, methods that are convenient for the rapid and
reliable molecular epidemiological analysis of these resistance
determinants are still required.
We previously applied PCR-restriction fragment length polymorphism
(PCR-RFLP) analysis to the differentiation of variant
blaSHV genes (3), extending the
molecular characterization of SHV
-lactamases using PCR-SSCP
analysis. However, PCR-SSCP analysis has a number of drawbacks as
described above. The PCR-RFLP technique is a simple and rapid
alternative but cannot identify all known mutations, such as those
affecting amino acids at positions 8, 238 (altering glycine to
alanine), or 240, according to Ambler's numbering scheme
(1). Thus, blaSHV-3,
blaSHV-4, blaSHV-7, and blaSHV-13 cannot be identified unambiguously by
PCR-RFLP analysis, unless the PCR-SSCP analysis is also applied
(3, 13). In the previous study, neither PCR-SSCP nor
PCR-RFLP analysis could differentiate the
blaSHV-1, blaSHV-6, and
blaSHV-8 genes (3). In addition, no
commercial supplies are available for restriction endonuclease
BcefI, used to demonstrate mutations affecting the amino
acid at position 205. Furthermore, 12 novel
blaSHV variants have also been reported
recently: blaSHV-14 (17),
blaSHV-16 (C. Arpin, R. Labia, F. Tessier, and
C. Quentin, GenBank accession no. AF072684),
blaSHV-18 (15),
blaSHV-19 to blaSHV-22
variants (5), blaSHV-23 (S. Y. Essack, L. M. C. Hall, and D. M. Livermore, GenBank
accession no. AF117747), blaSHV-25 and
blaSHV-26 (L. K. Siu, F. Y. Chang, and
M. H. Huang, GenBank accession no. AF208796 and AF227204,
respectively), blaSHV-27 (J. E. Corkill,
C. A. Hart, L. Cuevas, and J. Greensill, GenBank accession no.
AF293345), and blaSHV-28 (Y. Yu, W. Zhou, and Y. Chen, GenBank accession no. AF299299). This further complicates the
characterization of the genes of the blaSHV
family, and we have included them in our study.
Restriction site insertion-PCR (RSI-PCR) was first developed to detect
point mutations between closely related DNA sequences (4, 7,
12). Primers with one to three base mismatches near the 3' end
are used to modulate target restriction sites. In this study, RSI-PCR
has been applied to the detection of the mutations of
blaSHV genes that cannot be identified
unambiguously by PCR-RFLP. In addition, PCR-RFLP can theoretically be
applied to differentiate blaSHV-6,
blaSHV-8, blaSHV-14,
blaSHV-18 to blaSHV-23, and blaSHV-25 to
blaSHV-27, thus allowing almost all the
described blaSHV variants to be differentiated
easily and reliably.
(This work was presented in part at the 40th Interscience Conference on
Antimicrobial Agents and Chemotherapy, 17 to 20 September 2000.)
 |
MATERIALS AND METHODS |
Bacterial strains.
Eight standard strains were used in this
study, including Escherichia coli C600(R1010), encoding
blaSHV-1; E. coli C600(pMG229), encoding blaSHV-2; E. coli
J53-2(pUD18), encoding blaSHV-3;
Klebsiella pneumoniae K25, encoding
blaSHV-4; E. coli HB101(pAFF611),
encoding blaSHV-5; E. coli
C1A(pSLH06), encoding blaSHV-6; E. coli strain 2-75, encoding blaSHV-8; and
K. pneumoniae ATCC 700603, encoding blaSHV-18 (2, 10, 15, 16).
Primers.
Mismatch primers comprising at least 20 nucleotides
were designed with modification of one or two nucleotides near the 3' end based on the nucleotide sequence of the
blaSHV-1 flanking the primers; thus, a
restriction site is created on an amplimer of the
blaSHV-1 gene (Table 1). These included the
primers that detect mutations affecting amino acids at positions 8 (SspI), 179 (HinfI), 238 (BsrI), and
240 (NruI). A further mismatch primer pair was designed to
remove the PstI restriction site affecting the amino acid at
positions 208 to 209. This permits identification of mutants that carry
a PstI recognition site affecting the amino acid at position
205. The mismatch primers were designed using primer design software:
Primer3 from the PCR Jump Station. Pairs of primers that yielded
amplimer products not longer than 350 bp were chosen (4).
PCR amplification.
PCR amplification was performed in a
final volume of 25 µl as described previously (3) except
that dimethyl sulfoxide was excluded and 0.5 to 1 U of SuperTaq DNA
polymerase was used. In addition, 1.25 and 1.125 mM concentrations of
magnesium chloride were used for PCR amplification that detected
mutations affecting amino acids at position 238 and 240, respectively.
PCR amplification was carried out using predenaturation at 95°C for 3 min; followed by 30 cycles consisting of denaturation at 95°C for
30 s, annealing at 60°C for 30 s, and elongation at 72°C
for 30 s; and with a final elongation at 72°C for 5 min. The PCR
products were digested with restriction endonucleases according to the
manufacturer's instructions (BsrI, NruI, and
SspI were purchased from New England Biolabs,
PstI and HinfI were supplied from Promega and
GibcoBRL, respectively). After digestion, the products were analysed by gel electrophoresis using 3% low-melting-point agarose (Metaphore; FMC
Bio-Products, Flowgen, Staffordshire, United Kingdom). A 100-bp ladder
was used as a DNA size marker.
 |
RESULTS AND DISCUSSION |
In this study, mismatch primers were designed to identify
mutations affecting the amino acids at positions 8, 179, 205, 238, and
240. All blaSHV variants described to date are
derived from blaSHV-1 with one to seven amino
acid substitutions. Thus, the primers were designed to create a
restriction site specific to the blaSHV-1,
except the primer detecting mutations affecting the amino acid at
position 205. The latter primer was designed to delete a
PstI restriction site found just downstream at the nucleotides encoding amino acids 208 and 209. This site is present in
all blaSHV genes. The mismatch primer pair will
thus yield an amplimer that will only be digested by the
PstI restriction endonuclease if it is generated from genes
that carry a mutation that creates a PstI site, such as the
mutations that cause alterations in the amino acid at position 205. In
this study, target restriction endonucleases were chosen based on a
recognition site at least 5 bp in length, for their cost-effectiveness
and for their commercial availability.
When amplifying blaSHV-1, the primers, with the
exception of the primer pair that detects mutations affecting the amino
acid at position 205, all generated the expected novel restriction sites that yield fragments of the predicted sizes when digested by
their specific restriction endonucleases (Fig.
1 and 2).
Amplimers from blaSHV genes carrying mutations
remained undigested by these endonucleases. Since there is a
BsrI restriction site within the 248-bp product amplified by
a pair of primers identifying the mutation that alters the amino acid
at position 238 (Table 1) and the
mismatch primer creates a second BsrI restriction site, after digestion with BsrI amplimers from the wild type and
the mutant yielded fragments as predicted (Table 1 and Fig. 1). For the
primer pair designed to detect mutations affecting the amino acid at
position 205, the blaSHV-1 amplimer remained
undigested, whereas the mutant blaSHV amplimers
were digested to yield fragments of the appropriate sizes (Fig. 2).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 1.
Mutations of blaSHV genes
demonstrated by RSI-PCR analysis with various restriction
endonucleases. (a) Position 8 with SspI digestion; (b)
position 179 with HinfI digestion; (c) position 238 with
BsrI digestion. Lanes A to H, amplimers of
blaSHV genes blaSHV-1
(A), blaSHV-2 (B),
blaSHV-3 (C), blaSHV-4
(D), blaSHV-5 (E),
blaSHV-6 (F), blaSHV-8
(G), and blaSHV-18 (H) after digestion; lane I,
amplimer of blaSHV-1 gene before digestion; lane
M, 100-bp ladder.
|
|

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 2.
Mutations of blaSHV genes
demonstrated by RSI-PCR analysis with various restriction
endonucleases. (a) Position 240 with NruI digestion; (b)
position 205 with PstI digestion. Lanes A to E, amplimers of
blaSHV genes blaSHV-1
(A), blaSHV-2 (B),
blaSHV-3 (C), blaSHV-4
(D), and blaSHV-5 (E) after digestion; lane F
amplimer of blaSHV-1 gene before digestion; lane
M, 100-bp ladder.
|
|
As of 10 January 2001, (last date accessed by us) 29 variants of the
blaSHV gene have been deposited in GenBank. This
study also makes theoretical considerations for the identification of blaSHV-6, blaSHV-8,
blaSHV-14, blaSHV-18 to
blaSHV-23, and blaSHV-25 to blaSHV-27 using the PCR-RFLP technique.
DNASIS as described previously (2) and Webcutter 2.0 were
used to identify restriction endonucleases capable of distinguishing
the point mutations of these blaSHV genes. All
mutations of the blaSHV genes that can be
detected by PCR-RFLP analysis from a previous study (3) and this study are summarized in Table 2.
Although these studies make a theoretical PCR-RFLP analysis for the
differentiation of genes encoding SHV
-lactamases, the technique
relies on the high specificity of restriction endonucleases for their
restriction sites. Thus, amplimers of SHV mutant genes would yield
predicted PCR-RFLP patterns if mutations are present in their
nucleotide sequences as described. This technique has been proved to
identify blaSHV variants successfully as
predicted (3)
in this case, a novel gene,
blaSHV-27. The mutation affecting the amino acid at position 156 of the blaSHV-27 gene can be
detected easily using PCR-RFLP analysis with either BglI or
TaqI (data not shown).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Restriction patterns of PCR products showing mutations
affecting amino acids at various positions compared with
blaSHV-1
|
|
The RSI-PCR technique has been developed to extend the identification
of SHV
-lactamases by PCR-RFLP analysis as described previously
(3). By a combination of both techniques, genes encoding
the 27 SHV variants blaSHV-2 to
blaSHV-27 may be differentiated as proposed in
Table 3. Common
blaSHV variants such as
blaSHV-1 to blaSHV-5,
blaSHV-2a, blaSHV-11, and
blaSHV-12 (8, 9) may be
differentiated by detecting four mutations affecting the amino acids at
positions 35, 205, 238 (Gly
Ser), and 240 (Table 3). However, this
study suggests that other blaSHV variants that are uncommon may be underestimated due to the lack of methods suitable
for screening these genes in instances when many isolates are to be
characterized. The approach in Table 3 may be useful for the
differentiation of all known SHV
-lactamase genes described to date.
Although the nucleotide sequence of the gene previously designated
blaSHV-17 has recently been withdrawn from
GenBank, a novel SHV-type extended spectrum
-lactamase also
designated SHV-17 by Winokur et al. (P. L. Winokur, D. L. Desalvo, R. N. Jones, and M. A. Pfaller, Abstr. 39th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. 2045, 1999) has
three amino acid substitutions at positions 43 (Arg
Ser), 238 (Gly
Ser), and 240 (Gln
Lys) identical to those described in the
sequence withdrawn from GenBank. Thus, this SHV variant is included in
the identification scheme. In the present study, the PCR-RFLP technique
cannot differentiate the blaSHV-28 gene from the
blaSHV-1 gene since there are no restriction endonucleases that can detect a mutation affecting the amino acid at
position 7 of the blaSHV-28 gene. However,
RSI-PCR could be applied to identify this mutation. In addition, the
gene encoding SHV-16 may be distinguished from that encoding SHV-1 by
the sizes of their amplimers using a pair of primers identifying
mutation at position 179. The amplimer generated from
blaSHV-16 will yield a fragment of 250 bp,
whereas that of blaSHV-1 will give a 235-bp fragment since the product of the blaSHV-16 gene
has an extra five amino acids, starting at position 167.
The PCR-RFLP and RSI-PCR techniques can be used as screening methods
for groups of strains when many isolates are to be characterized or
when it is not possible to apply nucleotide sequence determination. Either PCR-RFLP or RSI-PCR analysis can also be applied to confirm new
mutations demonstrated by nucleotide sequence analysis, allowing new
SHV variants to be differentiated. The flexibility of RSI-PCR, with the
ability to create or remove restriction sites, makes this the method of
choice for characterizing newly described variants of
blaSHV. A limitation of this technique is that
it can only detect mutations at sites where the current range of
primers create restriction sites. In new epidemiological studies, there
may be blaSHV variants with mutations in
previously undescribed positions. Nucleotide sequence analysis is thus
still required to confirm absolutely the nature of any
blaSHV encountered in such studies.
PCR-RFLP and RSI-PCR techniques are simple and rapid and require only
basic molecular biology equipment, namely, a thermocycler and simple
electrophoresis apparatus. These techniques are readily applied to
epidemiological studies of the genes encoding variant SHV
-lactamases and may easily be extended to the discrimination of
other polymorphic resistance determinants.
 |
ACKNOWLEDGMENTS |
We thank the Royal Thai Government for providing a scholarship
for Aroonwadee Chanawong.
We are grateful to G. Jacoby, M. H. Nicholas, E. Collatz, G. Arlet, and J. K. Rasheed for providing strains that produce the standard SHV
-lactamases. We are also grateful to John Corkill for
providing us with a strain producing SHV-27.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Microbiology, University of Leeds, Leeds LS2 9JT, United Kingdom.
Phone: 44 113 233 5597. Fax: 44 113 233 5649. E-mail:
p.m.hawkey{at}leeds.ac.uk.
 |
REFERENCES |
| 1.
|
Ambler, R. P.,
A. F. W. Coulson,
J. M. Frere,
J. M. Ghuysen,
B. Joris,
M. Forsman,
R. C. Levesque,
G. Tiraby, and S. G. Waley.
1991.
A standard numbering scheme for the class A -lactamases.
Biochem. J.
276:269-270.
|
| 2.
|
Arlet, G.,
M. Rouveau, and A. Philippon.
1997.
Substitution of alanine for aspartate at position 179 in the SHV-6 extended-spectrum -lactamase.
FEMS Microbiol. Lett.
152:163-167[Medline].
|
| 3.
|
Chanawong, A.,
F. H. M'Zali,
J. Heritage,
A. Lulitanond, and P. M. Hawkey.
2000.
Characterisation of extended-spectrum -lactamases of the SHV family using a combination of PCR-single strand conformational polymorphism (PCR-SSCP) and PCR-restriction fragment length polymorphism (PCR-RFLP).
FEMS Microbiol. Lett.
184:85-89[Medline].
|
| 4.
|
Daffonchio, D.,
S. Borin,
A. Consolandi, and C. Sorlini.
1999.
Restriction site insertion-PCR (RSI-PCR) for rapid discrimination and typing of closely related microbial strains.
FEMS Microbiol. Lett.
180:77-83[CrossRef][Medline].
|
| 5.
|
Essack, S. Y.,
L. M. C. Hall,
D. G. Pillay,
M. L. Mcfadyen, and D. M. Livermore.
2001.
Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum -lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa.
Antimicrob. Agents Chemother.
45:88-95[Abstract/Free Full Text].
|
| 6.
|
Garbarg-Chenon, A.,
V. Godard,
R. Labia, and J. C. Nicolas.
1990.
Nucleotide sequence of SHV-2 -lactamases gene.
Antimicrob. Agents Chemother.
34:1444-1446[Abstract/Free Full Text].
|
| 7.
|
Haliassos, A.,
J. C. Chomel,
L. Tesson,
M. Baudis,
J. Kruh,
J. C. Kaplan, and A. Kitzis.
1989.
Modification of enzymatically amplified DNA for the detection of point mutations.
Nucleic Acids Res.
17:3606[Free Full Text].
|
| 8.
|
Heritage, J.,
F. H. M'Zali,
D. Gascoyne-Binzi, and P. M. Hawkey.
1999.
Evolution and spread of SHV extended-spectrum -lactamases in Gram-negative bacteria.
J. Antimicrob. Chemother.
44:309-318[Abstract/Free Full Text].
|
| 9.
|
Jacoby, G. A., and A. A. Medeiros.
1991.
More extended-spectrum -lactamases.
Antimicrob. Agents Chemother.
35:1697-1704[Free Full Text].
|
| 10.
|
Jacoby, G. A., and L. Sutton.
1991.
Properties of plasmids responsible for production of extended-spectrum -lactamases.
Antimicrob. Agents Chemother.
35:164-169[Abstract/Free Full Text].
|
| 11.
|
Kim, J., and H.-J. Lee.
2000.
Rapid discriminatory detection of genes coding for SHV -lactamases by ligase chain reaction.
Antimicrob. Agents Chemother.
44:1860-1864[Abstract/Free Full Text].
|
| 12.
|
Kwok, S.,
D. E. Kellog,
N. McKinney,
L. Goda,
C. Levenson, and J. J. Sninsky.
1990.
Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type-1 model studies.
Nucleic Acids Res.
18:999-1005[Abstract/Free Full Text].
|
| 13.
|
M'Zali, F. H.,
D. M. Gascoyne-Binzi,
J. Heritage, and P. M. Hawkey.
1996.
Detection of mutations conferring extended-spectrum activity on SHV -lactamase using polymerase chain reaction single strand conformational polymorphism (PCR-SSCP).
J. Antimicrob. Chemother.
37:797-802[Abstract/Free Full Text].
|
| 14.
|
Nüesch-Inderbinen, M. T.,
F. H. Kayser, and H. Hächler.
1997.
Survey and molecular genetics of SHV -lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12.
Antimicrob. Agents Chemother.
41:943-949[Abstract].
|
| 15.
|
Rasheed, J. K.,
G. J. Anderson,
H. Yigit,
A. M. Queenan,
A. Doménech-Sánchez,
J. M. Swenson,
J. W. Biddle,
M. J. Ferraro,
G. A. Jacoby, and F. C. Tenover.
2000.
Characterization of the extended-spectrum -lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18.
Antimicrob. Agents Chemother.
44:2382-2388[Abstract/Free Full Text].
|
| 16.
|
Rasheed, J. K.,
C. Jay,
B. Metchock,
F. Berkowitz,
L. Weigel,
J. Crellin,
C. Steward,
B. Hill,
A. A. Medeiros, and F. C. Tenover.
1997.
Evolution of extended-spectrum -lactam resistance (SHV-8) in a strain of Escherchia coli during multiple episodes of bacteremia.
Antimicrob. Agents Chemother.
41:647-653[Abstract].
|
| 17.
|
Yuan, M.,
L. M. C. Hall,
J. Hoogkamp-Korstanje, and D. M. Livermore.
2001.
SHV-14, a novel -lactamase variant in Klebsiella pneumoniae isolates from Nijmegen, The Netherlands.
Antimicrob. Agents Chemother.
45:309-311[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, July 2001, p. 2110-2114, Vol. 45, No. 7
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2110-2114.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Szabo, D., Melan, M. A., Hujer, A. M., Bonomo, R. A., Hujer, K. M., Bethel, C. R., Kristof, K., Paterson, D. L.
(2005). Molecular Analysis of the Simultaneous Production of Two SHV-Type Extended-Spectrum Beta-Lactamases in a Clinical Isolate of Enterobacter cloacae by Using Single-Nucleotide Polymorphism Genotyping. Antimicrob. Agents Chemother.
49: 4716-4720
[Abstract]
[Full Text]
-
Paterson, D. L., Bonomo, R. A.
(2005). Extended-Spectrum {beta}-Lactamases: a Clinical Update. Clin. Microbiol. Rev.
18: 657-686
[Abstract]
[Full Text]
-
Munday, C. J., Whitehead, G. M., Todd, N. J., Campbell, M., Hawkey, P. M.
(2004). Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum {beta}-lactamases in York, UK. J Antimicrob Chemother
54: 628-633
[Abstract]
[Full Text]
-
Heritage, J., Chambers, P. A., Tyndall, C., Buescher, E. S.
(2003). SHV-34: an extended-spectrum {beta}-lactamase encoded by an epidemic plasmid. J Antimicrob Chemother
52: 1015-1017
[Abstract]
[Full Text]